OA

Oaktree Acquisition Corp. III Life Sciences

OACC·NASDAQ

$10.63

-0.19%
Financial ServicesShell Companies

Oaktree Acquisition Corp. III Life Sciences focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to acquire companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was incorporated in 2024 and is based in Los Angeles, California.

At a Glance

Live Snapshot
Market Cap$261.31M
EPS0.3000
P/E Ratio35.43
Earnings Date
o

Oaktree Acquisition Corp. III Life Sciences Street Expectations Map

OACC · NASDAQ

No Target Data

No analyst price targets available for oacc.

o

Oaktree Acquisition Corp. III Life Sciences Forward Estimates of Revenue

OACC · NASDAQ
Latest Revenue
0.00
FY 2025
Avg Estimate
N/A
FY N/A
Estimate Range
N/A - N/A
Analyst Spread

Forward Growth Analysis

OutlookCautious

Analyst skepticism evident—carefully evaluate risks before investment decisions.

o

Oaktree Acquisition Corp. III Life Sciences Forward Estimates of Net Income

OACC · NASDAQ
Latest Net Income
7.29M
FY 2025
Avg Estimate
N/A
FY N/A
Estimate Range
N/A - N/A
Analyst Spread

Forward Growth Analysis

OutlookCautious

Analyst skepticism evident—carefully evaluate risks before investment decisions.

o

Oaktree Acquisition Corp. III Life Sciences Forward Estimates of EPS

OACC · NASDAQ
Latest EPS
0.30
FY 2025
Avg Estimate
N/A
FY N/A
Estimate Range
N/A - N/A
Analyst Spread

Forward Growth Analysis

OutlookCautious

Analyst skepticism evident—carefully evaluate risks before investment decisions.

o

Oaktree Acquisition Corp. III Life Sciences Forward Estimates of EBIT

OACC · NASDAQ
Latest EBIT
-1.20M
FY 2025
Avg Estimate
N/A
FY N/A
Estimate Range
N/A - N/A
Analyst Spread

Forward Growth Analysis

OutlookCautious

Analyst skepticism evident—carefully evaluate risks before investment decisions.

o

Oaktree Acquisition Corp. III Life Sciences Forward Estimates of EBITDA

OACC · NASDAQ
Latest EBITDA
-1.20M
FY 2025
Avg Estimate
N/A
FY N/A
Estimate Range
N/A - N/A
Analyst Spread

Forward Growth Analysis

OutlookCautious

Analyst skepticism evident—carefully evaluate risks before investment decisions.

o

Oaktree Acquisition Corp. III Life Sciences Forward Estimates of SG&A Expense

OACC · NASDAQ
Latest SG&A Expense
1.20M
FY 2025
Avg Estimate
N/A
FY N/A
Estimate Range
N/A - N/A
Analyst Spread

Forward Growth Analysis

OutlookCautious

Analyst skepticism evident—carefully evaluate risks before investment decisions.

o

Oaktree Acquisition Corp. III Life Sciences Insider Positioning

OACC · NASDAQ

During the last 12 months, there has been no insider trading activity reported for OACC.

3 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

3-6 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

6-9 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

9-12 Months

Bought

0

0.00

Sold

0

0.00

Net Activity

+0

+$0

Top Buyers

No buying activity

Top Sellers

No selling activity

Insider Activity Analysis

Net Insider Sentiment

Neutral

No insider trading activity reported. This could indicate blackout periods, lack of conviction, or regulatory restrictions.

Insider Participation

No Activity

No insider trading activity reported from any insiders in the past year.